Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Entrada Therapeutics, Inc. Entrada Therapeutics Reports Second Quarter 2024 Financial Results August 13, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Announces $100 Million Registered Direct Offering June 24, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy June 24, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference June 03, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ May 16, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Reports First Quarter 2024 Financial Results May 07, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results March 13, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics to Present at Upcoming Investor Conferences February 07, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Promotes Nathan J. Dowden to President January 03, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy November 22, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Reports Third Quarter 2023 Financial Results November 07, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics to Present at Upcoming Investor Conferences October 12, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy September 21, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community September 07, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics to Present at Upcoming Investor Conferences August 29, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Appoints Gina Chapman to its Board of Directors August 10, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Reports Second Quarter 2023 Financial Results August 08, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy August 01, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference June 06, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Reports First Quarter 2023 Financial Results May 10, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors April 04, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference March 29, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results March 06, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference February 27, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1) February 09, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable January 09, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy December 19, 2022 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference November 22, 2022 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Reports Third Quarter 2022 Financial Results November 07, 2022 From Entrada Therapeutics, Inc. Via GlobeNewswire Tickers TRDA Entrada Therapeutics Appoints Biotech Industry Leader Mary Thistle to Its Board of Directors May 04, 2021 From Entrada Therapeutics, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.